Scarica l'app Stockscreener
51.45
0.77%
-0.40
Dopo l'orario di chiusura:
50.77
-0.68
-1.32%
Precedente Chiudi:
$51.85
Aprire:
$52
Volume 24 ore:
74,367
Relative Volume:
0.99
Capitalizzazione di mercato:
$141.60M
Reddito:
$697.00K
Utile/perdita netta:
$-37.19M
Rapporto P/E:
-1.3649
EPS:
-37.6952
Flusso di cassa netto:
$-29.34M
1 W Prestazione:
-4.72%
1M Prestazione:
+2.02%
6M Prestazione:
-34.11%
1 anno Prestazione:
-90.34%
Intervallo 1D:
$49.70
$52.56
Intervallo di 1 settimana:
$49.70
$55.21
Portata 52W:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
51.45 | 142.71M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Craig Hallum | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Price to book forward of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Spruce Biosciences (SPRB) Joins Russell 3000 Index - GuruFocus
Spruce Biosciences Joins the Russell 3000® Index - BioSpace
Spruce Biosciences, Inc.(NasdaqCM:SPRB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 2500 Growth Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 2000 Index - marketscreener.com
Spruce Biosciences added to Russell 3000 index By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 2000 Value Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM:SPRB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Spruce Biosciences added to Russell 3000 index - Investing.com
Spruce Biosciences, Inc.(NasdaqCM:SPRB) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 3000E Growth Benchmark - marketscreener.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell Microcap Index - marketscreener.com
Price to sales forward of Spruce Biosciences, Inc. – BOATS:SPRB - TradingView
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to Russell 3000E Index - marketscreener.com
Spruce Biosciences Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock RallyEarnings Beat Streak - dars.gov.et
Enterprise value to EBIT forward of Spruce Biosciences, Inc. – BOATS:SPRB - TradingView
Enterprise value to EBITDA forward of Spruce Biosciences, Inc. – BOATS:SPRB - TradingView
Price to earnings forward of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
Spruce Biosciences, Inc. Actuals & Estimates (NASDAQ:SPRB) - TradingView
SPRB Forecast — Price Target — Prediction for 2027 - TradingView
Spruce Biosciences Inc (SPRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spruce Biosciences names Agnieszka Jurecka as VP medical affairs - Investing.com UK
Spruce Biosciences names Agnieszka Jurecka as VP medical affairs By Investing.com - Investing.com South Africa
Spruce Biosciences Signals Commercial Shift with Key Hire for Rare Disease Drug - BriefGlance
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs - Business Wire
Spruce Biosciences Inc (SPRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spruce Biosciences Inc (SPRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Spruce Biosciences Inc (SPRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spruce Biosciences Inc (SPRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spruce Biosciences Inc (SPRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Spruce Biosciences Inc (SPRB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Spruce Biosciences Inc (SPRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spruce Biosciences Inc (SPRB) Institutional Confidence - TradingKey
SPRB Initiates Coverage by Guggenheim -- Price Target Announced at $123 - GuruFocus
Guggenheim Initiates Spruce Biosciences(SPRB.US) With Buy Rating, Announces Target Price $123 - Moomoo
BBIO Welcomes New Leadership in Marketing and Finance - GuruFocus
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller - Investing News Network
Spruce Biosciences names two executives ahead of potential FDA decision By Investing.com - Investing.com Nigeria
Spruce Biosciences names two executives ahead of potential FDA decision - Investing.com
Spruce Biosciences Appoints Eric Jordan and Tina Gullotta to Leadership Roles Ahead of Potential TA-ERT Launch - citybiz
Spruce Biosciences Builds Its Commercial War Chest for a Rare Disease Bet - BriefGlance
SPRB Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentEarnings Cycle Outlook - newsline.com
SPRB News | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
SPRB Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com Australia
Spruce Biosciences (SPRB) Reports Promising Long-Term Results fo - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com UK
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B Presented at the 18th International MPS Symposium - Investing News Network
Spruce says long-term TA-ERT data presented at MPS Symposium - TipRanks
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spruce Biosciences Inc Azioni (SPRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):